



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

19th September 2014 - New research

TOZADENANT CLINICAL TRIALS FOR PARKINSON'S DISEASE

Lancet Neurology [2014] 13 (8) : 767-776 (R.A.Hauser, C.W.Olanow, K.D.Kieburztz, E. Pourcher, A.Docu-Axelerad, M.Lew, O.Kozyolkin, A.Neale, C.Resburg, U.Meya, C.Kenney, S.Bandak) Complete abstract : <http://www.ncbi.nlm.nih.gov/pubmed/25008546>

Clinical trials assessed the use 60mg, 120mg, 180mg, or 240mg tozadenant in people with Parkinson's Disease who were being treated with L-dopa and who had motor fluctuations that involved at least 2.5 hours off-time per day. Tozadenant (SYN115) is an inhibitor of the adenosine 2a (A2a) receptor that is being developed for the treatment of Parkinson's Disease. For more information go to Biotie Therapies :

http://www.biotie.com/en/product_portfolio/product_portfolio/syn115



Compared with the use of a placebo, daily off-time was reduced by more than an hour when taking either 120mg or 180mg tozadenant. The most common adverse events were dyskinesia (16% of people taking 120mg, 20% of people taking 180mg), nausea (11% of people taking 120mg, 12% of people taking 180mg), dizziness (5% of people taking 120mg, 13% of people taking 180mg). Tozadenant, 60 mg twice daily, was not associated with a significant reduction in off-time.

Tozadenant, 240 mg twice daily, was associated with an increased rate of discontinuation because of adverse events that occurred in 20% of people taking that dosage. The researchers concluded that Tozadenant at 120 or 180 mg twice daily was generally well tolerated and was effective at reducing off-time. Further investigation of tozadenant treatment in phase 3 trials is warranted.

<http://www.viartis.net/parkinsons.disease/news/140919.pdf>

mail@viartis.net

©2014 Viartis